{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-030559","form_type":"8-K","ticker":"PVLA","cik":"0001583648","company_name":"PALVELLA THERAPEUTICS, INC.","filed_at":"2024-10-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.874638+00:00","generated_at":"2026-05-30T21:30:45.564275+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Palvella (merger target of Pieris) awarded up to $2.6M FDA grant for Phase 3 rare skin disease trial","bullets":["FDA Office of Orphan Products Development awarded Palvella up to $2.6M over 4 years to support Phase 3 SELVA trial of QTORIN rapamycin gel for microcystic lymphatic malformations.","Program has FDA Breakthrough Therapy and Fast Track designations; trial is single-arm, baseline-controlled.","Grant one of seven awarded out of 51 applications in FY2024; underscores high unmet need in rare genetic skin disease.","Positive development for Palvella, which is being acquired by Pieris Pharmaceuticals via merger announced July 23, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-030559","json":"https://secwatch.observer/filing/0001437749-24-030559.json","markdown":"https://secwatch.observer/filing/0001437749-24-030559.md","text":"https://secwatch.observer/filing/0001437749-24-030559.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583648/000143774924030559/0001437749-24-030559-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583648/000143774924030559/pirs20241003_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T21:30:45.564275+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}